Please login to the form below

Not currently logged in
Email:
Password:

Janssen ‘extremely disappointed’ by NICE’s Olysio guidance

Hepatitis C drug only recommended use for one out of three licenced indications

Janssen logo

Janssen has released a statement saying they are 'extremely disappointed' with NICE's decision to recommend Olysio (simeprevir) for only one out of three of its licenced indications for hepatitis C.

NICE's appraisal consultation document (ACD) has recommended the drug for the treatment of chronic hepatitis C genotype 1 infection, but did not recommend it for use in combination with sofosbuvir for patients who are unable to tolerate an interferon-based regimen with genotypes 1 or 4 hepatitis C.

Around one in three people infected with hepatitis C will eventually develop liver cirrhosis, when normal liver tissue is replaced by scar tissue. The aim of treatment is to clear the virus from the blood to prevent the progression of liver disease and to prevent the transmission of the virus.

Peter Barnes, medical director at Janssen, said: “We are pleased that simeprevir has been recommended for the treatment of patients with genotype 1 hepatitis C when used in combination with peginterferon and ribavirin.

“However, we are disappointed with the preliminary recommendations from NICE for genotype 4 patients and those who are intolerant to interferon and could therefore benefit from the use of a treatment regime that does not include it.”

“We believe there is an unmet need in these patient groups that simeprevir can help address and that our submission to NICE demonstrates the cost-effectiveness of its use,” he added.

The setback comes after Johnson & Johnson – Janssen's parent company -reported a 21% increase in pharma turnover in the second-quarter of 2014, with $831m worth of sales driven by rocketing sales of Olysio.

The appraisal committee recommended that NICE requests a detailed rationale from the company about whether the clinical effectiveness in people with genotype 1 can be generalised to people with genotype 4 hepatitis C. NICE also recommends that clinical data, including genotype and sustained virological response at 12 weeks, is collected for all people treated with Olysio in the NHS.

Janssen said it continues to work with NICE and other stakeholders to try to find a solution to change their preliminary decision.

Article by
Kirstie Pickering

23rd September 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics